In patients with EGFR-mutated NSCLC who had progressed on EGFR TKI treatment, both sntilimab plus IBI305 and chemotherapy, as well as sintilimab plus chemotherapy, demonstrated increased costs and improved survival compared to chemotherapy alone (Table 1). This evidence concerns the gene EGFR and non-small cell lung carcinoma.